کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
10157393 1666461 2018 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
The inherent risks associated with newly traded biopharmaceutical firms
ترجمه فارسی عنوان
خطرات ذاتی مربوط به شرکت های تجاری بیوفارمانی که اخیرا معامله شده اند
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی بیوتکنولوژی یا زیست‌فناوری
چکیده انگلیسی
Here, we provide a comprehensive study related to the risks of all biopharmaceutical firms going public in the USA between 1996 and 2015. We found 355 firms that met our requirements for being in the sector that focuses on creating drugs for humans. Collectively, these firms spent approximately US$86.9 billion on research and development (R&D) during this time. They also lost approximately US$69.3 billion in combined net income. We also examine the delisting of these firms from a public market, their number of collaborators at the initial public offering (IPO), and estimate the percentage ownership by other biopharmaceutical firms at the IPO.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Drug Discovery Today - Volume 23, Issue 9, September 2018, Pages 1680-1688
نویسندگان
, ,